]Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
August 31, 2022
Peer-ReviewedResults
Among 223,128 subjects from the city of Itajaí, 159,560 were 18 years old or up and were not infected by COVID-19 until July 7, 2020, from which 45,716 (28.7%) did not use and 113,844 (71.3%) used ivermectin. Among ivermectin users, 33,971 (29.8%) used irregularly (up to 60 mg) and 8,325 (7.3%) used regularly (more than 180 mg).
COVID-19 infection rate was 49% lower for regular users (3.40%) than non-users (6.64%)
The infection rate was 32% lower for irregular users than non-users
Among COVID-19 participants, regular users were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users.
The hospitalization rate was reduced by 100% in regular users compared to both irregular users and non-users (p < 0.0001), and by 29% among irregular users compared to non-users
Mortality rate was 92% lower in regular users than non-users
Risk of dying from COVID-19 was 86% lower among regular users than non-users
Conclusion
Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.
https://www.cureus.com/articles/111851-regular-use-of-ivermectin-as-prophylaxis-... We should ask why the TGA didn't allow this to be prescribed in Australia.